Stereotaxis Q1 revenue $6.5M, net loss $5.3M; reiterates double-digit growth outlook

Stereotaxis, Inc.

2023-Q1 EPS reported -$0.07 revenue$6,548,000

Revenue $6.5M vs $7.0M prior year; excluding catheter royalties, essentially flat.
Net loss $5.3M vs $4.1M; adjusted net loss (excl stock comp) $2.7M vs $1.6M.
Gross margin 59%; recurring revenue gross margin 79%, system margin 7% on low volumes.
Cash $26.8M with no debt; year-end cash expected $22-24M; sees double-digit revenue growth in 2023.
Orders received for two Genesis systems; expects increase in system orders vs 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Stereotaxis, Inc. reported the first quarter ended March 31, 2023 results: revenue $6.5 million, net income ($5.3) million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $6.5 million
Net income: ($5.3) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

on May 19-21 and sharing meaningful updates on our innovation strategy at the conference.” 2023 First Quarter Financial Results Revenue for the first quarter of 2023 totaled $6.5 million compared to $7.0 million in the prior year first quarter. Revenue in these quarters were equivalent excluding catheter royalties received in the prior year. System revenue for

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Stereotaxis, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-015876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.